The prevalence of substance use disorders and psychiatric disorders as a function of psychotic symptoms

Drug and Alcohol Dependence

Volumn 131, Issue 1-3, 2013, Pages 78-84

  Lechner, William V ^a   Dahne, Jennifer ^b   Chen, Kevin W ^c   Pickover, Alison ^d   Richards, Jessica M ^b   Daughters, Stacey B ^e   Lejuez, C W ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d University of Memphis   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Comorbidity inpatient treatment; Psychiatric disorders; Psychotic symptoms; Substance dependence

Indexed keywords

AMPHETAMINE; CANNABIS;

ADULT; AGED; ALCOHOLISM; ARTICLE; BORDERLINE STATE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE; FEMALE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RESIDENTIAL CARE; SUBSTANCE ABUSE;

ADULT; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PSYCHOTIC DISORDERS; QUESTIONNAIRES; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

CANNABIS;

EID: 84878567930     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.12.003     Document Type: Article

References (31)

1. Barnett J.H., Fletcher P.C., Cappa S.F., Abutalebi J., Démonet J.-F., Fletcher P.C., Garrard P. Cognition in schizophrenia. Cognitive Neurology: A Clinical Textbook 2008, 419-446. Oxford University Press, New York. S.F. Cappa, J. Abutalebi, J.-F. Demonet, P.C. Fletcher, P. Garrard (Eds.).
2. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Bio. Psychiatry 2001, 50:71-83.
3. Chen K.W., Banducci L.G., Macatee R.J., Lavelle A., Daughters S.B., Lejuez C.W. An examination of psychiatric comorbidities as a function of gender and substance type within an inpatient substance use treatment program. Drug Alcohol Depend. 2011, 118:92-99.
4. Curran C., Byrappa N., Mcbride A. Psychosis: systematic review. Br. J. Psychiatry 2004, 185:196-204.
5. Dalmau A., Bergman B., Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine, and opiates: do dopaminergic stimulants facilitate psychiatric illness?. Eur. Psychiatry 1999, 14:366-371.
6. Degenhardt L., Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol. Med. 2001, 31:659-668.
7. Dekker N., Linszen D.H., De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009, 42:350-360.
8. Farrell M., Boys A., Bebbington P., Brugha T., Coid J., Jenkins R., Lewis G., Meltzer H., Marsden J., Singleton N., Taylor C. Psychosis and drug dependence: results from a national survey of prisoners. Br. J. Psychiatry 2002, 181:393-398.
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. The structured clinical interview for DSM-III-R personality disorders (SCID-II): I. description. J. Personal Disord. 1995, 9:83-91.
10. Fonseca-Pedrero E., Paino M., Lemos-Giráldez S., Sierra-Baigrie S., Ordoñez-Camblor N., Muñiz J. Early psychopathological features in Spanish adolescents. Psicothema 2011, 23:87-93.
11. Granholm E., Ben-Zeev D., Link P.C. Social disinterest attitudes and group cognitive-behavioral social skills training for functional disability in schizophrenia. Schizophr. Bull. 2009, 35:874-883.
12. Granholm E., Ben-Zeev D., Link P.C., Bradshaw K.R., Holden J.L. Mobile assessment and treatment for schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr. Bull. 2011, 38:414-425.
13. Horsfall J., Cleary M., Hunt G.E., Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv. Rev. Psychiatry 2009, 17:24-34.
14. Koob G.F. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 2010, 1314:3-14.
15. Koreen A.R., Siris S.G., Chakos M., Alvir J. Depression in first-episode schizophrenia. Am. J. Psychiatry 1993, 150:1643-1648.
16. Kuzenko N., Sareen J., Beesdo-Baum K., Perkonigg A., Höfler M., Simm J., Lieb R., Wittchen H.U. Associations between use of cocaine, amphetamines, or psychedelics and psychotic symptoms in a community sample. Acta Psychiatr. Scand. 2011, 123:466-474.
17. Lataster T., Wichers M., Jacobs N., Mengelers R., Derom C., Thiery E., Van Os J., Myin-Germeys I. Does reactivity to stress cosegregate with subclinical psychosis?. A general population twin study. Acta Psychiatr. Scand. 2009, 119:45-53.
18. Laurens K.R., Hodgins S., Maughan B., Murray R.M., Rutter M.L., Taylor E.A. Community screening for psychotic-like experiences and other putative antecedents of schizophrenia in children aged 9-12 years. Schizophr. Res. 2007, 90:130-146.
19. Lichlyter B., Purdon S., Tibbo P. Predictors of psychosis in individuals with primary stimulant addictions. Addict. Behav. 2011, 36:137-139.
20. McKetin R., McLaren J., Lubman D.I., Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006, 101:1473-1478.
21. McMillan K.A., Enns M.W., Cox B.J., Sareen J. Comorbidity of Axis I and II mental disorders with schizophrenia and psychotic disorders: findings from the national epidemiologic survey on alcohol and Related Conditions. Can. J. Psychiatry 2009, 54:477-486.
22. Michail M., Birchwood M. Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia. Br. J. Psychiatry 2009, 195:234-241.
23. Miller F.T., Abrams T., Dulit R., Fyer M. Psychotic symptoms in patients with borderline personality disorder and concurrent axis I disorder. Hosp. Community Psychiatry 1993, 44:59-61.
24. Nuevo R., Chatterji S., Verdes E., Naidoo N., Arango C., Ayuso-Mateos J.L. The continuum of psychotic symptoms in the general population: a cross-national study. Schizophr. Bull. 2012, 38:475-485.
25. Ringen P.A., Melle I., Birkenæs A.B., Engh J.A., Færden A., Jónsdóttir H., Nesvag R., Vaskinn A., Friis S., Larsen F., Opjordsmoen S., Sundet K., Andreassen O.A. Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatr. Scand. 2008, 117:133-138.
26. Rosller W., Hengartner M.P., Angst J., Ajdacic-Grss V. Linking substance use with symptoms of subclinical psychosis in a community cohort over 30 years. Addiction 2012, 107:1174-1184.
27. Salo R., Flower K., Kielstein A., Leamon M.H., Nordahl T.E., Galloway G.P. Psychiatric comorbidity in methamphetamine dependence. Psychiatr. Res. 2011, 186:356-361.
28. Smith M.J., Thirthalli J., Abdallah A.B., Murray R.M., Cottler L.B. Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr. Psychiatry 2009, 50:245-250.
29. Tarrier N., Beckett R., Harwood S., Baker A., Yusupoff L., Ugarteburu I. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. outcome. Br. J. Psychiatry 1993, 162:524-532.
30. Trull T.J., Sher K.J., Minks-Brown C., Durbin J., Burr R. Borderline personality disorder and substance use disorders: a review and integration. Clin. Psychol. Rev. 2000, 20:235-253.
31. Zanarini M.C., Frankenburg F.R., Chauncey D.L., Gunderson J.G. The Diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Compr. Psychiatry 1987, 28:467-480.